United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $522.37, for a total value of $4,962,515.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $169,479,289.91. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics Price Performance

Shares of UTHR stock opened at $525.82 on Friday. The stock has a market capitalization of $22.32 billion, a PE ratio of 19.41, a P/E/G ratio of 1.75 and a beta of 0.58. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The business has a 50-day moving average of $544.65 and a 200 day moving average of $532.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the firm earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. Analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $648.33.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.